World's Best Scientists 2026 revealed!
Robert M. Sharkey

Robert M. Sharkey

D-Index & Metrics

Medicine

D-Index
86
Citations
22907
World Ranking
14285
National Ranking
435

Overview

Robert M. Sharkey is affiliated with the University of Fukui in Japan and has a focused research profile in the field of Medicine, with a significant number of publications related to Oncology.

Their research encompasses several key subfields:

  • Oncology
  • Radiology, Nuclear Medicine and Imaging
  • Pulmonary and Respiratory Medicine
  • Molecular Biology
  • Pharmacology

The scientist's work covers a range of main topics, especially related to cancer and molecular therapies, including:

  • HER2/EGFR in Cancer Research
  • Radiopharmaceutical Chemistry and Applications
  • Lung Cancer Research Studies
  • Neuroendocrine Tumor Research Advances
  • Cancer therapeutics and mechanisms
  • Monoclonal and Polyclonal Antibodies Research
  • Advanced Breast Cancer Therapies

Robert M. Sharkey has contributed to multiple papers over recent years, including:

  • "Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial" (2021) published in Annals of Oncology
  • "Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial" (2020) published in Annals of Oncology
  • "Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy" (2020) published in Expert Opinion on Biological Therapy
  • "Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer" (2020) published in Oncotarget
  • "Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer" (2020) published in Journal of Nuclear Medicine

Key frequent co-authors associated with Robert M. Sharkey include:

  • David M. Goldenberg
  • William A. Wegener
  • Thomas M. Cardillo
  • Aditya Bardia
  • Trishna Goswami

The main publication venues where Robert M. Sharkey's work has appeared frequently include:

  • Oncotarget
  • Annals of Oncology
  • Journal of Nuclear Medicine
  • Expert Opinion on Biological Therapy
  • European Journal of Nuclear Medicine and Molecular Imaging

Best Publications

  • Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.

    Aditya Bardia;Ingrid A Mayer;Linda T Vahdat;Sara M Tolaney

  • Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)

    David M. Goldenberg;Thomas M. Cardillo;Serengulam V. Govindan;Edmund A. Rossi

  • A Novel Method of 18F Radiolabeling for PET

    William J. McBride;Robert M. Sharkey;Habibe Karacay;Christopher A. D'Souza

  • Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.

    Aditya Bardia;Ingrid A. Mayer;Jennifer R. Diamond;Rebecca L. Moroose

  • Antibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy

    David M. Goldenberg;Robert M. Sharkey;Giovanni Paganelli;Jacques Barbet

  • First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors.

    Alexander N. Starodub;Allyson J. Ocean;Manish A. Shah;Michael J. Guarino

  • Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting

    Edmund A. Rossi;David M. Goldenberg;Thomas M. Cardillo;William J. McBride

  • Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys

    Thomas M. Cardillo;Serengulam V. Govindan;Robert M. Sharkey;Preeti Trisal

  • Targeted therapy of cancer: new prospects for antibodies and immunoconjugates.

    Robert M. Sharkey;David M. Goldenberg

  • Carcinoembryonic Antigen in Histopathology: Immunoperoxidase Staining of Conventional Tissue Sections

    D M Goldenberg;R M Sharkey;F J Primus

  • Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers.

    Thomas M. Cardillo;Serengulam V. Govindan;Robert M. Sharkey;Preeti Trisal

  • Survival Improvement in Patients With Medullary Thyroid Carcinoma Who Undergo Pretargeted Anti–Carcinoembryonic-Antigen Radioimmunotherapy: A Collaborative Study With the French Endocrine Tumor Group

    Jean-François Chatal;Loïc Campion;Françoise Kraeber-Bodéré;Stephane Bardet

  • Multifunctional Antibodies by the Dock-and-Lock Method for Improved Cancer Imaging and Therapy by Pretargeting

    David M. Goldenberg;Edmund A. Rossi;Robert M. Sharkey;William J. McBride

  • A novel facile method of labeling octreotide with (18)F-fluorine.

    Peter Laverman;William J. McBride;Robert M. Sharkey;Annemarie Eek

  • Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody.

    D M Goldenberg;J A Horowitz;R M Sharkey;T C Hall

  • Perspectives on Cancer Therapy with Radiolabeled Monoclonal Antibodies

    Robert M Sharkey;David M Goldenberg

  • Improved 18F Labeling of Peptides with a Fluoride-Aluminum-Chelate Complex

    William J. McBride;Christopher A. D’Souza;Robert M. Sharkey;Habibe Karacay

  • The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target

    David M. Goldenberg;Rhona Stein;Robert M. Sharkey

  • Immunocytochemical detection of carcinoembryonic antigen in conventional histopathology specimens.

    David M. Goldenberg;Robert M. Sharkey;F. James Primus

  • Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial.

    A. Bardia;W.A. Messersmith;E.A. Kio;J.D. Berlin

Frequent Co-Authors

David M. Goldenberg
David M. Goldenberg Immunomedics (United States)
Chien-Hsing Chang
Chien-Hsing Chang Northwestern University
Edmund A. Rossi
Edmund A. Rossi Immunomedics (United States)
Hans J. Hansen
Hans J. Hansen Eisai (Japan)
Aditya Bardia
Aditya Bardia Harvard University
Wim J.G. Oyen
Wim J.G. Oyen Humanitas University
Otto C. Boerman
Otto C. Boerman Radboud University
Wells A. Messersmith
Wells A. Messersmith University of Colorado Boulder
Gary L. Griffiths
Gary L. Griffiths National Institutes of Health
Jacques Barbet
Jacques Barbet University of Nantes

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in medicine doesn’t always mean becoming a doctor. There are many related online degrees and career pathways that allow you to make a significant impact in healthcare. Nursing, healthcare administration, and nutrition are popular areas where you can build a fulfilling profession—often with the flexibility and convenience of online study.

Registered nurses seeking to advance can explore asn to fnp bridge programs, which help transition from Associate Degree in Nursing to Family Nurse Practitioner roles. For those interested in advancing their credentials without traditional in-person requirements, online rn-bsn programs without clinicals offer convenient pathways.

Beyond nursing, aspiring leaders can improve hospital operations and patient care by pursuing cahme-accredited online mha programs, meeting top standards in healthcare administration. Alternatively, those passionate about wellness and disease prevention may consider a bachelor's in nutrition online, opening doors in clinical nutrition, public health, and research.

Each pathway offers unique opportunities to contribute to healthcare and can be an excellent complement or alternative to traditional medical degrees.

Best Scientists Citing Robert M. Sharkey

Trending Scientists